Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2657-2665

  Li, Qing Quan ^a   Xu, Jing Da ^a   Wang, Wen Juan ^a   Cao, Xi Xi ^a   Chen, Qi ^a   Tang, Feng ^b   Chen, Zhong Qing ^b   Liu, Xiu Ping ^a,c   Xu, Zu De ^b,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; KAPLAN-MEIERS ESTIMATE; MESODERM; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; TWIST TRANSCRIPTION FACTOR;

EID: 65249155400     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2372     Document Type: Article

References (39)

1. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997;390:335-6.
2. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
3. Yang JM,XuZ,WuH,Zhu H,Wu X, Hait WN. Over-expression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003;1:420-7.
4. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442 -54.
5. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 2004;48:365-75.
6. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005;132: 3151-61.
7. Moody SE, Perez D, Pan TC, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005;8:197-9.
8. Yang Y, Pan X, Lei W, et al. Regulation of transforming growth factor-|βl-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res 2006;66:8617-24.
9. Yang J, Mani SA, Weinberg RA. Exploring a new Twist on tumor metastasis. Cancer Res 2006;66: 4549-52.
10. Mironchik Y, Winnard PT, Jr.,Vesuna F, et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 2005;65:10801-9.
11. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:1 -11.
12. Kang Y, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004; 118:277-9.
13. Hoek K, Rimm DL,Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64: 5270-82.
14. Yang J, Mani SA, DonaherJL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
15. Kwok WK, Ling MT, LeeTW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153-62.
16. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003;4:657-65.
17. Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired Taxol resistance in human cancer cells. Oncogene 2004;23:474-82.
18. Okada H, Danoff TM, Kalluri R, et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997;273:563-74.
19. Lee JM, Dedhar S, Kalluri R,Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-81.
20. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
21. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
22. Comijn J, Berx G, Vermassen P, et al. The two-handed e box binding zinc finger protein sip1 down-regulates e-cadherin and induces invasion. Mol Cell 2001;7: 1267-78.
23. Carver EA, Jiang R, Lan Y, Oram KF, Gridley T. The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol 2001;21: 8184-8.
24. Yang JM, Medina GY, Vassil DJ, Liao AD, Hait J. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Bio chem Biophys Res Commun 1999;266:167-73.
25. Yamauchi K, Yang M, Hayashi K, et al.Hoffman. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 2008;68:516-20.
26. Kajiyama H, Shibata K,Terauchi M, et al. Chemore- sistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007;31: 277-83.
27. Sherr Charles J. Cancer cell cycles. Science 1996; 274:1672-7.
28. Kerbel RS, Waghorne C, Korczak B, Lagarde A, Breitman ML. Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surv 1988;7:597-629.
29. Kerbel RS, Korczak B, Lagarde A. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990;5: 87-132.
30. Su ZZ, Austin VN, Zimmer SG, Fisher PB. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 1993; 8:1211-9.
31. Li QQ, Wang WJ, Xu ZD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 2007;98:1064-9.
32. Li QQ, Wang WJ, Xu ZD, et al. Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 2007;98:1767-74.
33. Leptin M, Grunewald B. Cell shape changes during gastrulation in Drosophila. Development 1990;110: 73-84.
34. Hosono S, Kajiyama H,Terauchi M, et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. BrJ Cancer 2007;96:314-20.
35. Kwok WK, Ling MT, Lee TW, et al. Up-regulation of Twist in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153-62.
36. Song LB, Liao WT, Mai HQ, et al.The clinical significance of Twist expression in nasopharyngeal carcinoma. Cancer Lett 2006;242:258-65.
37. Maestro R, Dei Tos AP, Hamamori Y, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-17.
38. Okorokov AL, Orlova EV, Kingsbury SR, et al. Molecular structure of human Geminin. Nat Struct Mol Biol 2004;11:1021-2.
39. Saito S'i, Yamaguchi H, Higashimoto Y, et al. Phosphorylation site interdependence of human p53 posttranslational modifications in response to stress. J Biol Chem 2003; 278: 37536-44.